Ceterix’s three new patents help protect its unique products and methods, such as its NovoStitch suture passer that is used in the repair of meniscal tears and other soft-tissue joint injuries. The technology can also be used in minimally invasive hip and shoulder procedures.
“These new patents provide added support to our efforts to improve patients’ lives through innovation,” said John McCutcheon, president and CEO of Ceterix. “The NovoStitch technology is now protected by more than 180 issued claims.”
More articles on devices:
Integra LifeSciences releases reinforcement matrix for tendon injuries
The new Amedica: Reorganized as a start-up with focus and ambition
TissueGen to expand spinal cord injury repair program — 5 key updates
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
